# Pizarra — PT-pseudo_33c8cd4571fd (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_33c8cd4571fd
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. M. Jansen (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.411 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 11.0 ng/mL
  - Prostate volume: 29.2 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.884623 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.41. Prostate volume 29 mL. csPCa 0.88.

Vitals: weight 64 kg, height 177 cm, BMI 20.4, BP 140/87 mmHg, HR 59 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation necessitated a scheduled MRI review.

History: At 71 years old, the retired primary school teacher has tracked a gradual PSA rise since late 2022, calculating a velocity of 0.96 ng/mL annually. Residing with his wife, he stays active through daily twenty-minute walks and light gardening. Lower urinary complaints sit at a moderate 12 on the IPSS, dominated by nocturia and a diminished stream, handled without intervention. Fifteen alcohol units are consumed each week. Haematuria, pelvic discomfort, and unexplained weight loss are denied. Well-controlled hypertension relies on valsartan, lisinopril, and metoprolol, with cardiology parameters remaining stable. Recent podiatry for nail care and a standard hearing assessment both returned unremarkable. He does not smoke, reports steady energy, and experiences no sleep disturbances. Clinical records note a prior biopsy bucket of None.

Physical examination: DRE: The prostate presents as symmetrically smooth, lacking palpable nodules or asymmetry, aligning with a normal assessment. General inspection shows a well-nourished individual (BMI 20.4), blood pressure reading 140/87 mmHg, and a regular pulse of 59 bpm. Peripheral oedema and lymphadenopathy are absent.

Patient info: retired primary school teacher; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 15 units / week; exercise Walking 20 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Audiology — hearing test.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.86 +/- 0.12   (95% CI 0.55-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 8.1 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=12.0, age=71.0, psad=0.411, dre_ord=0.0, vol=29.2, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5, PSA=12.0, Age=71, PSA Density=0.411, DRE=Normal, Volume=29.2, Prior Biopsy=None) and failed to incorporate the PSA velocity (0.96 ng/mL/yr) or the csPCa predicted probability (0.884623).
The prior cannot weigh the clinical significance of the rapid PSA rise (0.96 ng/mL/yr) or the high predicted csPCa probability (0.884623), which are critical clinical factors not explicitly weighted by the simple classifier.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.86), but the guideline criterion is based only on PI-RADS $\ge 3$, which is met. However, the prior ignores the context that the patient is biopsy-naive and the guideline track record is based on a cohort where the specific combination of high PI-RADS and high PSA velocity is not explicitly factored in. The prior's high confidence interval suggests the decision is robust, but this ignores the possibility that the specific combination of factors might lead to a different outcome than the general cohort average.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - to confirm the rate of rise and context for the PI-RADS 5 score
previous GP / urology notes - to see if any prior clinical suspicion or LUTS history is documented
laboratory panel - to check for any other relevant lab markers
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion, and the track record shows that this criterion matched the reading urologist in every one of the 24 biopsy-naive cases.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_33c8cd4571fd", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 20 February 2025 | Institution: Catharina Ziekenhuis, Eindhoven\nClinical indication: Persistent PSA elevation (12.0 ng/mL) and follow-up assessment.\n\nFINDINGS:\nMeasuring 29.2 mL, the gland shows a focal hypointense focus in the left peripheral zone at mid-gland on T2-weighted sequences (approx. 12 x 8 x 10 mm). DWI/ADC reveals marked restricted diffusion. Early, intense enhancement appears on DCE. No capsular breach or seminal vesicle invasion.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone. Prostate volume 29.2 mL yielding a PSA density of 0.411 ng/mL/mL. csPCa predicted probability 0.884623."}
get_psa_trend
{"case_id": "PT-pseudo_33c8cd4571fd", "psa_trend": [{"date": "Sep 2022", "val": 3.6}, {"date": "Apr 2023", "val": 4.9}, {"date": "Dec 2023", "val": 6.6}, {"date": "Jul 2024", "val": 8.9}, {"date": "Mar 2025", "val": 12.0}]}
get_previous_notes
{"case_id": "PT-pseudo_33c8cd4571fd", "previous_notes": [{"date": "01 Nov 2024", "author": "Dr. M. Jansen (GP)", "text": "On 01 Nov 2024, a review occurred after PSA climbed to 11.0 ng/mL in July. Persistent elevation alongside his age prompted scheduling a multiparametric MRI via the urology referral pathway. Attendance for imaging results was noted."}]}
get_lab_results
{"case_id": "PT-pseudo_33c8cd4571fd", "laboratory_results": [{"name": "PSA", "val": "12.0 ng/mL", "date": "19 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.02 ng/mL", "date": "19 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "19 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "15.5 g/dL", "date": "19 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.3 x10^9/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "294 x10^9/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "83 umol/L", "date": "19 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "19 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "17.8 nmol/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "51 U/L", "date": "19 Jan 2025", "flag": ""}, {"name": "LDH", "val": "159 U/L", "date": "19 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "5.8 %", "date": "19 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The pathology report was not retrieved, which is necessary to determine the ISUP grade or Gleason score of any prior cancer.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone (12 x 8 x 10 mm) with marked restricted diffusion.
- PSA trend: Rapid rise from 6.6 ng/mL (Dec 2023) to 12.0 ng/mL (Mar 2025), with a velocity of 0.96 ng/mL/yr.
- csPCa predicted probability: 0.884623.

AGAINST sampling this patient now:
- MRI report: No capsular breach or seminal vesicle invasion noted.
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the high-risk PI-RADS 5 finding and the rapid PSA velocity, which aligns with the guideline criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI revealed a PI-RADS 5 lesion, which is the primary driver for sampling according to the guideline criterion. This finding is supported by the rapid PSA velocity of 0.96 ng/mL/yr and the high csPCa predicted probability of 0.884623. The statistical prior suggested biopsy, and the retrieved MRI report confirmed the high-risk finding, leading to convergence on this decision.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
